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den cardiac death secondary to malignant ventri-
cular arrhythmias (VAs). Among the 3 BS ECG 
types described, type 1 BS ECG is diagnostic and 
considered at higher-risk for sudden cardiac de-
ath, according to most authors, characterized by 
a coved ST-segment elevation (>2 mm-0.2 mV), 
trending downwards, followed by a negative 
T-wave in leads V1 and/or V2 positioned in the 
second, third, or fourth intercostal space, occur-
ring intermittently or continuously, either spon-
taneously or after intravenous sodium-channel 
blockers administration, such as ajmaline and/or 
flecainide1. Arrhythmic sudden death risk-stratifi-
cation remains controversial1, in particular in re-
gards to the role of electrophysiology study (EPS) 
with programmed ventricular stimulation (PES), 
which is considered relevant if positive but is not 
considered risk-free if negative. Other factors 
such as family history of sudden death, symptoms 
and drug challenge affect the prognosis. EPS has 
a class IIB recommendation in current interna-
tional guidelines1, because of the low reprodu-
cibility and high variability of protocols used in 
various centers2,3. It has recently been described 
a case of different VAs inducibility depending on 
the presence or absence of ECG anomalies indu-
ced by drug challenge4. Also, the treatment of BS 
patients is not unanimous, such as the timing for 
internal cardioverter defibrillator (ICD) or quini-
dine. Epicardial ablation of the right ventricular 
outflow tract (RVOT) to reduce ICD discharges 
has recently been described, confirming the pre-
sence of a sectorial vulnerability5,17. We report a 
type 1 BS patient who experienced different VAs 
inducibility depending on the timing of PES, with 
and without ajmaline administration. 
We analyzed the sequence of events to manage 
BS in this patient in order to better understand its 
Abstract. – OBJECTIVE: The role of electro-
physiology study in Brugada syndrome (BS) sud-
den cardiac death risk stratification remains con-
troversial and seems to depend on the phenotypic 
expression of the channelopathy. Ajmaline has a 
key role in the diagnosis of BS. We observed that 
programmed electrical stimulation (PES) of the 
right ventricular outflow tract (RVOT), only when 
type 1 BS ECG is unmasked by ajmaline adminis-
tration, induces ventricular arrhythmias. 
CASE REPORT: We describe a case of ventric-
ular fibrillation induction by PES of the RVOT 
when type 1 BS ECG is revealed by ajmaline, in a 
patient with a baseline dynamic intermittent type 
1 and 2 BS ECG.
CONCLUSIONS: The heterogeneous clinical 
presentations of BS are due to the underlying 
mechanisms. PES of the RVOT during positive 
ajmaline test maximizes the channelopathy and 
therefore sudden cardiac death risk-stratifica-
tion in BS.
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Abbreviations 
EPS = Electrophysiology study; BS = Brugada syn-
drome; RVOT = Right ventricular outflow tract; PES = 
Programmed electrical stimulation; VT = Ventricular ta-
chycardia; VF = Ventricular fibrillation.
Introduction
Brugada syndrome (BS) is an ion channels 
genetic disorder characterized by typical electro-
cardiographic (ECG) anomalies responsible for 
major complications such as syncope and/or sud-
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dynamic mechanisms responsible for the existing 
controversies between centers, and for the wide 
spectrum of clinical presentations, including oc-
casional fatal events. 
 
Case Report 
A 68-year-old man was referred for suspected 
BS because of the appearance of a J-wave and a 
convex upwards ST-segment elevation >2 mm in 
leads V1-V2-V3 at peak cycle ergometer stress test 
(Figure 1). His cardiovascular risk-factors were: 
male sex, age, second-degree systemic hyperten-
sion, type IIB dyslipidemia, hyperhomocysteine-
mia, hyperuricemia, prior smoking habits, and 
family history of sudden death (a 50-year-old un-
cle died suddenly). The patient, without structural 
heart disease, reported a prior syncopal episode, 
and episodes of persistent atrial fibrillation trea-
ted by successful electrical cardioversion. Multi-
ple 12-lead ECGs showed sinus rhythm (SR), ho-
rizontal axis, PQ interval 160 msec, QRS interval 
80 msec with a small progressive R wave in V1-
V2, J-point and ST-segment variability (Figure 2). 
A second cycle ergometer stress test was negative 
for myocardial ischemia and showed no additio-
nal ST-segment alterations compared to baseline 
(Figure 3). Echocardiography was normal (LVEF 
0.64, normal diastolic pattern), except for a mild 
tricuspid valve regurgitation and a non-signifi-
cant mitral valve regurgitation. Chest X-ray and 
hemogasanalysis were normal. The laboratory te-
sts showed normal electrolytes, cholesterol > 250 
mg/dL, triglycerides > 200 mg/dL. 
The patient underwent sodium-channel blockers 
challenge. Baseline conditions were SR, heart rate 
(HR) 80 bpm, PQ 160 msec, incomplete right bund-
le branch block (RBBB) QRS 105 msec, J-point and 
ST-segment elevation of 0.14 mV in V1 and 0.18 mV 
in V2 concave upwards (V1-V2 in the second inter-
costal space) compatible with type 2 BS ECG, QTc 
0.41 sec. 
Diagnostic drug-challenge performed by intra-
venous administration of ajmaline (1 mg/kg over 
10 min) unmasked an abnormal response compa-
tible with “coved” type 1 BS ECG with SR HR 
78 bpm, PR 180 msec, QRS 150 msec, complete 
RBBB with J-point and ST-segment elevation of 
0.38 mV convex upwards and negative T-waves in 
Figure 1. Outpatient ergom-
eter stress test; it is diagnostic 
for BS, characterized by a coved 
ST-segment elevation (>2 mm-
0.2 mV) in V1, V2. 
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V1-V2 at the second intercostal space; J-point and 
ST-segment elevation of 0.14 mV in aVL, 0.1 mV 
in D1, QTc 0.45 sec (Figure 4). 
We waited for about 40 min after ajmaline test 
(double of its half-life), and the ECG turned into 
type 2 BS with SR, HR 80 bpm, QRS 105 msec, 
incomplete RBBB with J-point and ST-segment 
elevation concave upwards of 0.14 mV in V1 and 
0.18 mV in V2 at the second intercostal space, 
QTc 0.41 sec (Figure 4). 
VAs risk stratification was, then, performed 
with PES from the right ventricular apex (RVA) 
and the RVOT by double extra-stimuli up to ven-
tricular effective refractory period (VERP) of 
500-300-210 msec and 400-350-210 msec without 
VAs induction (Figure 5). We, then, repeated PES 
after a new administration of ajmaline (0.5 mg/
kg in 10 min) and during the restoration of type 1 
BS ECG, from the RVA and the RVOT by double 
extra-stimuli up to VERP of 500-300-210 msec 
and 400-350-200 msec. The intervals were AH 
125 msec, HV 55 msec, VERP <250 msec. PES 
from the RVA induced only ventricular couples, 
whereas PES from the RVOT induced a repro-
ducible self-terminated symptomatic ventricular 
tachycardia (VT) followed by ventricular fibrilla-
tion (VF) with a cycle length of 260 msec, HR 
230 bpm (Figure 6). A dual-chamber ICD was 
implanted, per international guidelines (1), after 
informed consent was obtained. The patient was 
discharged in good clinical conditions, and was 
advised to follow BS and ICD recommendations.
Discussion
We describe a different VAs inducibility in the 
same patient, during the same EPS, by PES of the 
RVOT without and with ajmaline administration, 
without and with type 1 BS ECG maximization. 
The active presence of the channelopathy is re-
sponsible for type 1 BS ECG pattern. This con-
dition has been reported to ease the induction of 
malignant VAs at EPS4. 
The role of EPS in arrhythmic sudden cardiac 
death risk stratification remains controversial3,6,7. 
Current international guidelines recommend EPS 
with class IIB1. Its low reproducibility is explai-
ned by the highly variable protocols used in va-
rious centers3,7,8. However, a recent study10 with 
a 20-year follow-up showed that EPS is a good 
predictor of outcomes in BS individuals, but not 
absolute. According to Makimoto et al9, VAs in-
ducibility with single or double extra-stimuli in 
Figure 2. Multiple 12-lead ECGs; it is not diagnostic for BS.
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patients with type 1 BS ECG is a negative pro-
gnostic indicator, compared to the protocol with 
triple extra-stimuli9. Other known factors that 
affect VAs inducibility at EPS are the presence 
of symptoms, male sex, a conduction delay with 
prolonged HV interval7, and first-degree AV 
block11, supporting the hypothesis of the con-
duction/depolarization anomaly. We also descri-
bed a case of inducible VF in a BS patient with 
pre-existing RBBB, supporting the role of con-
duction disorders as negative prognostic factors8. 
The conduction disturbances are associated with 
repolarization dispersion in BS and may worsen 
the prognosis12.
The controversial role of EPS in risk-stratifi-
cation could depend on the dynamic phenotypic 
channelopathy expression7. International gui-
delines recommend provocative drug tests with 
Figure 3. Ergometer stress test in hospital; it is not diagnostic for BS or ischemic heart disease.
Figure 4. Ajmaline test, it is diagnostic for BS.
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intravenous administration of sodium-channel 
blockers in class IC1, because of their diagnostic 
key role when BS is suspected. They can unmask 
BS pattern13 by unbalancing the transmembrane 
ion fluxes equilibrium in favor of the repolarizing 
Ito current, resulting in J-wave and ST-segment 
elevation in the right precordial leads. Since a 
negative EPS could be interpreted as a low-risk 
non-type 1 BS, or depend on the dynamic nature 
of the ECG modifications and on its unclear re-
producibility, when type 1 BS is suspected drug 
challenge is mandatory. 
In this case, VAs induction by PES occurred 
after maximizing type 1 BS ECG during ajmaline 
administration, and did not occur otherwise. PES 
induced VF only when type 1 BS ECG anomalies 
were present and maximized by ajmaline, while 
it failed to induce VAs in the presence of type 2 
Figure 5. EPS + PES without effect ajmaline; not induce VT / VF.
Figure 6. Left: EPS+PES without effect Ajmaline not induce VT/VF. Right: EPS+PES effect of Ajmaline induces VT/VF.
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BS ECG. A similar case was characterized by a 
different VAs inducibility in different centers de-
pending on the presence or absence of the altered 
type 1 BS ECG unmasked by ajmaline4.
In this patient, RVOT PES induced VAs during 
type 1 BS ECG maximization as opposed to RVA 
PES. RVOT is the most vulnerable area in BS14, 
with electrophysiological and structural abnor-
malities. The electrophysiological anomalies are 
dispersion of repolarization and/or slow discon-
tinuous ventricular conduction1,15 and depolari-
zation12,16. The repolarization anomaly involves 
phase 1 of the action potential in the epicardial 
cells of the RVOT, which has a configuration 
“spike and dome”, leading to an electric transmu-
ral gradient between the endocardium and the 
epicardium (J-wave on ECG) and predisposing 
to polymorphic VT that often degenerates into 
FV. In fact, the onset of VAs is due to phase 2 
re-entry of the action potential, which develops 
when trans-membrane ionic fluxes alterations 
cause the plateau phase loss in some infundibular 
epicardial regions, with considerable shortening 
of the action potential duration and occurrence 
of a transmural electric gradient. Conduction di-
sturbances are often observed in BS, suggesting 
the involvement of mild RVOT and conduction 
system structural anomalies, which are the ar-
rhythmogenic substrate in combination with 
functional electrical anomalies, according to the 
depolarization hypothesis15. A BS case of RVOT 
fibrosis associated with conduction anomalies has 
been described, and may explain the underlying 
mechanisms for reentry and VF15. Substrate hete-
rogeneity represents an additional risk-factor for 
VAs, and some mild or diffuse RVOT structural 
anomalies include fibrosis, reduced gap junctions, 
collagen deposition14. RVOT ablation to reduce 
ICD discharges has been described, confirming 
such sectorial vulnerability5,17.
Conclusions
PES of the most vulnerable areas such as the 
RVOT, and BS phenotypic expression maximi-
zation with ajmaline may induce VAs. A critical 
review of the induction timing and technique, in 
this case, allowed us to postulate that fatal events 
in BS may happen when two factors are combi-
ned: ventricular extra-stimuli or ectopies, and the 
greatest expression of the channelopathy depen-
ding on multiple factors. It is otherwise hard to 
induce malignant VAs. EPS poor reproducibility 
and non-proper risk-stratification are due to the 
variability of protocols used in various centers. 
Our observations confirm that BS phenotype he-
terogeneity and high variability require standardi-
zed risk-stratification protocols that may improve 
patient selection and timing for ICD implantation, 
when no history of cardiac arrest is present. Fur-
ther studies are required to return to EPS its de-
served prognostic value.
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